KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $1.14.

  • Emergent BioSolutions' Debt to Equity fell 1254.96% to $1.14 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.14, marking a year-over-year decrease of 1254.96%. This contributed to the annual value of $1.37 for FY2024, which is 9990.72% up from last year.
  • As of Q3 2025, Emergent BioSolutions' Debt to Equity stood at $1.14, which was down 1254.96% from $1.25 recorded in Q2 2025.
  • Emergent BioSolutions' 5-year Debt to Equity high stood at $1.37 for Q4 2024, and its period low was $0.32 during Q4 2022.
  • Over the past 5 years, Emergent BioSolutions' median Debt to Equity value was $0.64 (recorded in 2023), while the average stood at $0.76.
  • As far as peak fluctuations go, Emergent BioSolutions' Debt to Equity crashed by 3565.22% in 2022, and later surged by 14736.27% in 2024.
  • Over the past 5 years, Emergent BioSolutions' Debt to Equity (Quarter) stood at $0.5 in 2021, then crashed by 35.65% to $0.32 in 2022, then surged by 112.77% to $0.69 in 2023, then soared by 99.91% to $1.37 in 2024, then decreased by 17.19% to $1.14 in 2025.
  • Its Debt to Equity stands at $1.14 for Q3 2025, versus $1.25 for Q2 2025 and $1.2 for Q1 2025.